Inhalation CDMO Bespak recently announced that it will close its site in Research Triangle Park, NC, USA by the end of the first quarter of 2025. Bespak spun out from Recipharm earlier this year with the stated purpose of focusing on the transition of MDIs to LGWP propellants. According to the company's announcement, it will be moving "selected product … [Read more...] about Bespak announces closure of its North Carolina facilities
Products and Services
OzUK announces new GLP pilot plant for development of MDIs with LGWP propellants
CRO OzUK has announced the availability of a new GLP pilot plant designed for pilot and feasibility studies of both solution and suspension MDIs filled with low global warming potential (LGWP) propellants. OzUK announced plans for the new facility in December 2023. According to the company, the new facility meets ATEX (Atmosphères Explosibles) standards for safety, … [Read more...] about OzUK announces new GLP pilot plant for development of MDIs with LGWP propellants
Polyrizon raises $4.2 million for continued development of its intranasal hydrogels
Intranasal hydrogel maker Polyrizon announced that it has closed a $4.2 million IPO, with a possibility of the total rising to $4.82 million if Aegis Capital exercises an option to purchase additional shares. Polyrizon said that funds from the IPO will be used for development of its hydrogel products for nasal drug delivery, called Capture and Contain (C&C), a … [Read more...] about Polyrizon raises $4.2 million for continued development of its intranasal hydrogels
Honeywell announces agreement to supply HFO 1234ze for DevPro albuterol MDI, spin off of the advanced materials business
Honeywell announced that it has signed a long-term supply agreement with DevPro Biopharma related to the use of Honeywell's Solstice Air HFO-1234ze in DevPro's DP007 albuterol metered dose inhaler. Earlier this year, DevPro and CDMO Bespak announced that they were collaborating on development of the LGWP propellant MDI. Recipharm, which later spun out Bespak, and … [Read more...] about Honeywell announces agreement to supply HFO 1234ze for DevPro albuterol MDI, spin off of the advanced materials business
Aptar acquires SipNose nasal delivery technology
Aptar Pharma announced that it has acquired nasal delivery technology from Israeli nasal drug developer SipNose Nasal Delivery Systems. In addition to developing devices, SipNose has a pipeline of candidates developed in-house and candidates in development with partners, such as Noveome's ST266 secretome. According to Aptar, the company has acquired all of … [Read more...] about Aptar acquires SipNose nasal delivery technology
Bespak and H&T Presspart launch new GMP pilot-scale MDI filling line for LGWP propellants
CDMO Bespak, which spun out from Recipharm earlier this year, and device company H&T Presspart have announced that a new pilot-scale GMP line for filling MDIs with lower global warming potential (LGWP) propellants HFA-152a and HFO-1234ze is ready to begin manufacturing at Bespak's Holmes Chapel, UK, site. The two companies announced in April 2024 that they had … [Read more...] about Bespak and H&T Presspart launch new GMP pilot-scale MDI filling line for LGWP propellants
Aero Pump and Resyca launch Ultra Soft Nasal Pump Spray device
German spray pump manufacturer Aero Pump and soft mist inhaler developer Resyca have announced a partnership for the development and launch of a device called the Ultra Soft Nasal Pump Spray, which is now available for licensing. In January 2024, Resyca parent companies Recipharm (now Bespak) and Medspray announced that they had added development of soft mist nasal … [Read more...] about Aero Pump and Resyca launch Ultra Soft Nasal Pump Spray device
ARS launches Neffy nasal epinephrine nasal spray in the US
ARS Pharmaceuticals has launched Neffy epinephrine nasal spray in the US, the company said. In Auguest 2024, Neffy was approved by the FDA for the treatment of anaphylaxis in patients who weigh 30 kg or more. Earlier this month, ARS submitted an sNDA for a lower dose of Neffy for the treatment of anaphylaxis in children weighing 15 to 30 kg (33-66 lbs). European … [Read more...] about ARS launches Neffy nasal epinephrine nasal spray in the US
Iconovo reports positive feedback from the FDA regarding its ICOpre DPI and reacquisition of rights to the ICOone device
DPI developer Iconovo said that the FDA "has issued a positive guidance regarding the generic substitutability of the company's proprietary inhaler ICOpre with the original drug Breo Ellipta with respect to external design and operating principles" and indicated that the device is suitable for an ANDA for a generic of Breo Ellipta fluticasone furoate/vilanterol DPI. … [Read more...] about Iconovo reports positive feedback from the FDA regarding its ICOpre DPI and reacquisition of rights to the ICOone device
Ritedose to manufacture Verona’s Ohtuvayre inhaled ensifentrine
CDMO Ritedose Corporation announced that it will manufacture Verona Pharma's Ohtuvayre nebulized ensifentrine, which was approved by the FDA in June 2024 for the treatment of COPD. Also in June 2024, Ritedose announced that it was adding blow-fill-seal (BFS) capacity for an additional 180 million unit doses at its manufacturing facility in Columbia, SC, … [Read more...] about Ritedose to manufacture Verona’s Ohtuvayre inhaled ensifentrine